An assessment of the strategy and status of COVID-19 vaccination in India

Sneh Lata Gupta, Surbhi Goswami, Ananya Anand, Namrata Naman, Priya Kumari,Priyanka Sharma,Rishi K. Jaiswal

IMMUNOLOGIC RESEARCH(2023)

引用 3|浏览1
暂无评分
摘要
The COVID-19 disease continues to cause devastation for almost 3 years of its identification. India is one of the leading countries to set clinical trials, production, and administration of COVID-19 vaccination. Recent COVID-19 vaccine tracker record suggests that 12 vaccines are approved in India, including protein subunit, RNA/DNA, non-replicating viral vector, and inactivated vaccine. Along with that 16 more vaccines are undergoing clinical trials to counter COVID-19. The availability of different vaccines gives alternate and broad perspectives to fight against viral immune resistance and, thus, viruses escaping the immune system by mutations. Using the recently published literature on the Indian vaccine and clinical trial sites, we have reviewed the development, clinical evaluation, and registration of vaccines trial used in India against COVID-19. Moreover, we have also summarized the status of all approved vaccines in India, their associated registered clinical trials, manufacturing, efficacy, and their related safety and immunogenicity profile.
更多
查看译文
关键词
SARS-CoV-2,Covaxin,Covishield,Vaccination,Sputnik
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要